viewApricus Biosciences Inc

Apricus goes flat as FDA refuses to approve erectile dysfunction treatment

It’s the second time regulators have given the thumbs-down to Vitaros, with the FDA flagging concerns over one of the ingredients in the cream as well as with the manufacturing process

man with erectile dysfunction
Erectile dysfunction affects more than 20mln men in the US alone

Shares of Apricus Biosciences Inc (NASDAQ:APRI) lost almost two-thirds of their value on Friday after regulators once again refused to approve its Vitaros erectile dysfunction cream.

The news sent the stock plunging, with shares down 65.5% to US$1.10 shortly after midday.

Apricus had been hoping to sell the treatment, possibly through its commercial partner Allergan PLC (NYSE:AGN), to patients who can’t take oral tablets and are looking for less invasive options.

Pfizer Inc’s (NYSE:PFE) Viagra and Eli Lilly and Co’s (NYSE:LLY) Cialis are two of the best-selling ED drugs but they are associated with mild side-effects such as blurred vision and headaches, while other forms of treatment include injections and suppositories that must be inserted into the urethra.

Vitaros - which has been sold in Canada, Mexico, parts of the Middle East and much of Europe for several years by Apricus’ partner, Ferring International - is applied to the skin with a disposable applicator.

But the US Food and Drug Administration flagged safety concerns related to an ingredient in Vitaros - DDAIP.HCI - while it also identified deficiencies in its chemistry and manufacturing, the company said.

DDAIP.HCI helps absorb products into the skin and is a key part of Apricus’ drug delivery technology.

It’s not the first time the FDA has rejected Vitaros. Back in 2008 it refused to give the thumbs-up, with analysts noting that there were fears the treatment could cause cancer in patients or their sexual partners.

Had it have been accepted for sale in the US this time around, analysts reckon it could have raked in up to US$200mln a year within a few years of its launch.

Chief executive Richard Pascoe said the California-based firm will update investors in early March on its future plans for the drug.

Quick facts: Apricus Biosciences Inc

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Matador Mining Ltd nearing release of scoping study for Cape Ray gold project

  Matador Mining Ltd's (ASX:MZZ) executive director Adam Kiley tells Proactive's Andrew Scott they're getting to close to announcing a scoping study for its Cape Ray Gold Project in Newfoundland, Canada, which is expected to be released 'later this quarter'. ''Also in the past quarter...

17 hours ago

2 min read